Navigation Links
Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
Date:9/9/2013

LAUSANNE, Switzerland and KOLKATA, India, September 9, 2013 /PRNewswire/ --

Debiopharm Group (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections.

Debiopharm is willing to become a key player in the area of antibacterials to fulfill the increasing need of new classes of antibiotics to overcome resistance to current treatment.

Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimization of lead compounds whilst Debiopharm will provide drug development expertise and fund the development program.

“We foresee to increase our commitment in this field over next few months through additional partnerships and investments on other innovative targets” said David Deperthes, VP Business Development & Licensing. "We are very enthusiastic about this partnership with TCGLS for the development of novel antibiotics, their extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348. This partnership is key to us to establish a leadership position in the area of antibiotics” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group.

Swapan Bhattacharya, Managing Director of TCG Lifesciences commented: “We are indeed excited about this program which involves a challenging new target that could potentially address the vast incidence of nosocomial infections which plague healthcare facilities all over the world. Debiopharm’s developmental expertise combined with our medicinal chemistry capabilities and efficient discovery operations provide an attractive opportunity for accelerated discovery of novel drug candidates for clinical development.”

Antibiotic resistance and nosocomial infection

The CDC estimates that, each year, nearly 2 million people in the United States acquire an infection while in a hospital, resulting in 90,000 deaths. More than 70 percent of the bacteria that cause these infections are resistant to at least one of the antibiotics commonly used to treat them.

In a report, the European CDC states that at least 25,000 patients in the EU die each year from infections due to bacteria that are resistant to a number of marketed drugs.

About TCG Lifesciences Ltd.

TCGLS is a leading contract research services company in the area of early drug discovery and development. They started their operations in the year 2001 in India. Currently TCGLS is present  in the United States, Europe, Japan and Australia. The company has a strong talent pool of 800+ trained scientists, drawn from the best national and international institutes as well as the industry. Their services span from specific solutions to integrated discovery projects across multiple therapeutic areas with focus on Central Nervous System (CNS), Inflammation and Pain, Metabolic Disorders and Infectious Diseases.

For more information about TCG, please visit: http://www.tcgls.com

About Debiopharm Group

Debiopharm Group (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group, please visit: http://www.debiopharm.com.


    
    Debiopharm International SA Contact
    Beatrice Hirt
    Communication Coordinator
    beatrice.hirt@debiopharm.com
    Tel.: +41-(0)21-321-01-11

    CG Lifesciences Ltd Contact
    Rakesh C. Pandya
    Head - Finance
    rakesh.pandya@tcgls.com
    Tel.: +91-33-4000-3000

    Additional Media Contacts
    In London
    Maitland
    Brian Hudspith
    bhudspith@maitland.co.uk
    Tel.: +44-(0)20-7379-5151

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    martina.schwarzkopf@russopartnersllc.com
    Tel.: +1-212-845-4292



'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
4. Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
5. Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
6. Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
7. Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast
8. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Watson to Acquire Actavis Group for EUR4.25 Billion
11. CentraState and Freehold Radiology Group train physicians from China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):